APT Pharmaceuticals Inc.
APT Pharmaceuticals, Inc. is a drug development company focused on effective treatments for significant unmet medical needs. APT is looking to extend the reach of stalled specialty drugs, reviving and repurposing them for novel uses. The development of such drugs, often targeting critical diseases, addresses a huge pharmaceutical industry R&D gap.
APT's model allows the company to profitably pursue opportunities that appear too small for larger or less efficient organizations. Furthermore, APT has great flexibility in deal structure, making it an attractive partner. APT significantly improves its probability of success by working with well-characterized drugs that it has identified as promising candidates for further development.
APT received initial financing from Charter Life Sciences, Research Corporation Technologies and Vivo Ventures.
APT announced in October 2007 that it closed a $22 million Series A-2 round of financing. New investors Versant Ventures and Great Point Partners joined existing firms Vivo Ventures and Charter Life Sciences in the round. APT, which has received a total of $30 million in funding to date, is using the new funding to advance its development pipeline, which includes Pulminiq, a Phase III drug for prevention of lung transplant rejection, a novel cardioprotectant and several other projects.
Inventor/Founder
B. Lauren Charous, M.D., Allergy and Research Care Center at Milwaukee Medical Clinic
APT Contact
Stephen Dilly, M.B.B.S., Ph.D., CEO, Foster City, Calif., (650) 566-6457
RCT Contact
Shaun Kirkpatrick, RCT President and CEO, (520) 748-4400